Editas Medicine, Inc. (EDIT)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
EDIT price, last 12 months
Key stats
- Previous close
- $1.77
- Open
- $1.80
- Day range
- $1.70 – $1.83
- 52-week range
- $1.63 – $3.94
- Volume
- 1.9M
- Avg volume (20 days)
- 2.4M
- Market cap
- $334.9M
Performance
Technicals and fundamentals
About Editas Medicine, Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $334.9M